PT  - JOURNAL ARTICLE
AU  - Grzelak, Ludivine
AU  - Temmam, Sarah
AU  - Planchais, Cyril
AU  - Demeret, Caroline
AU  - Huon, Christèle
AU  - Guivel-Benhassine, Florence
AU  - Staropoli, Isabelle
AU  - Chazal, Maxime
AU  - Dufloo, Jeremy
AU  - Planas, Delphine
AU  - Buchrieser, Julian
AU  - Rajah, Maaran Michael
AU  - Robinot, Remy
AU  - Porrot, Françoise
AU  - Albert, Mélanie
AU  - Chen, Kuang-Yu
AU  - Crescenzo, Bernadette
AU  - Donati, Flora
AU  - Anna, François
AU  - Souque, Philippe
AU  - Gransagne, Marion
AU  - Bellalou, Jacques
AU  - Nowakowski, Mireille
AU  - Backovic, Marija
AU  - Bouadma, Lila
AU  - Fevre, Lucie Le
AU  - Hingrat, Quentin Le
AU  - Descamps, Diane
AU  - Pourbaix, Annabelle
AU  - Yazdanpanah, Yazdan
AU  - Tondeur, Laura
AU  - Besombes, Camille
AU  - Ungeheuer, Marie-Noëlle
AU  - Mellon, Guillaume
AU  - Morel, Pascal
AU  - Rolland, Simon
AU  - Rey, Felix
AU  - Behillil, Sylvie
AU  - Enouf, Vincent
AU  - Lemaitre, Audrey
AU  - Créach, Marie-Aude
AU  - Petres, Stephane
AU  - Escriou, Nicolas
AU  - Charneau, Pierre
AU  - Fontanet, Arnaud
AU  - Hoen, Bruno
AU  - Bruel, Timothée
AU  - Eloit, Marc
AU  - Mouquet, Hugo
AU  - Schwartz, Olivier
AU  - van der Werf, Sylvie
TI  - SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors
AID  - 10.1101/2020.04.21.20068858
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.21.20068858
4099  - http://medrxiv.org/content/early/2020/04/24/2020.04.21.20068858.short
4100  - http://medrxiv.org/content/early/2020/04/24/2020.04.21.20068858.full
AB  - It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile. Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre-epidemic individuals, 51 patients from Hôpital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors. Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented. We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C-terminal domain) by immunoprecipitation. Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use. High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV-2 or lentiviral-S pseudotypes. In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies. Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases. Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.Competing Interest StatementLG, ST, CP, CD, CH, FGB, IS, MC, JD, DP, JB, MMR, RR, FP, MA, KYC, BC, FD, FA, PS, MG, JB, MN, MB, LB, LLF, QLH, DD, AP, YY, LT, CB, MNU, GM, PM, SR, FR, SB, VE, AL, MAC, SP, NE, AF, BH, TB, ME, HM, OS and SVDW have no competing interest to declare. PC is the founder and CSO of TheraVectys.Funding StatementOS lab is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR- 10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), "TIMTAMDEN" ANR-14-CE14-0029, "CHIKV-Viro-Immuno" ANR-14-CE14-0015-01 and the Gilead HIV cure program. LG is supported by the French Ministry of Higher Education, Research and Innovation. ME lab is funded by Institut Pasteur, Labex IBEID (ANR-10-LABX-62-IBEID), Reacting, EU grant Recover, ANR Oh’ticks. HM received core grants from the G5 Institut Pasteur Program, the Milieu Intérieur Program (ANR-10-LABX-69-01) and INSERM. C.P. is supported by a fellowship from the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). SVDW lab is funded by Institut Pasteur, CNRS, Université de Paris, Santé publique France, Labex IBEID (ANR-10-LABX-62-IBEID), REACTing, EU grant RecoverAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).